2018-09-27 – Press release
Topas Therapeutics to Participate at Upcoming Industry and Scientific Events
Meet with Topas at the following industry events this fall:
- Sachs 18 th Annual Biotech in Europe Forum
- BIO-Europe® 2018
- Meetings around JP Morgan 36 th Annual Global Healthcare Conference
- Immunology of Diabetes Society Congress 2018
- Antigen-Specific Immune Tolerance Europe Conference
Hamburg, 27th September 2018 – Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based private platform company leveraging the natural tolerance induction capabilities of the liver, today announced that the Company will participate at the following conferences this fall:
Meet with Topas at the following industry events:
Sachs 18 th Annual Biotech in Europe Forum
October 4–5, 2018
Timm Jessen, CEO of Topas Therapeutics, will participate in the Autoimmune & Inflammatory Diseases Panel on October 4 th at 11:30 AM CET. He will also give a corporate presentation on October 4 th at 3:30 PM CET, and the Company will host 1X1 meetings at the event. To request a meeting with Topas, please sign up through the event’s meeting system.
The Sachs Forum attracts approximately 650 delegates interested in investing and partnering in the biotech and life science industry. This highly transactional event draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives attending. More information on the event can be found here.
November 5–7, 2018
Topas will host 1X1 meetings at this event. To request a meeting with Topas, please sign up through the event’s partneringONE meeting system. The 24 th annual global life science partnering event is expected to bring together over 4,000 executives from 2,200+ life science companies spanning an estimated 60+ countries to engage in one-to-one partnering. For more information, please click here.
Meetings around JP Morgan 36th Annual Global Healthcare Conference
January 8–11, 2019
San Francisco, CA, USA
During the week of the JP Morgan Global Healthcare Conference in San Francisco, Topas will meet with investors, potential partners and other interested parties. Please contact Timm Jessen (firstname.lastname@example.org) if you are interested in meeting that week.
Learn more about the Topas Particle Conjugates (TPC) technology platform at these upcoming scientific conferences:
Immunology of Diabetes Society Congress 2018
October 25–29, 2018
London, United Kingdom
The Company will attend this scientific conference. The conference is for researchers with an interest in the immunology of diabetes and autoimmunity as well as those interested in gaining a greater understanding of the disease and the development of new therapeutic strategies. For more information, click here.
Antigen-Specific Immune Tolerance Europe Conference
December 10–12, 2018
London, United Kingdom
Timm Jessen will give a talk entitled, “Liver Based Immune Tolerance Induction,” on December 12th at 9:30 AM GMT.
Tackling key R&D challenges, such as antigen identification, animal model predictability, translation and clinical design, this conference is the first European centric, dedicated platform that brings key decision makers together to successfully translate ground breaking science into a novel class of therapies to treat autoimmunity. Please click here for more details about the event.
About Topas Therapeutics GmbH
Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. Topas’ technology platform induces antigen-specific immune tolerance by harnessing the liver’s natural immunology capabilities. The Company has several proprietary programs; the lead one is in an orphan disease and is expected to enter the clinic in 2019. Topas has a research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction, a multi-year agreement with Boehringer Ingelheim to collaborate in the field of anti-drug antibodies and a co-development agreement with Evotec for a Type 1 diabetes program that is currently in pre-clinical testing. Topas’ investors include: Epidarex Capital, Gimv, EMBL Ventures, Evotec and BoehringerIngelheim Venture Fund.
For additional information, please visit: www.topas-therapeutics.com.